
    
      Heterosexual contact is now the primary route of transmission for HIV worldwide. This study
      is a phase 3 multi-center, fully-masked, randomized, placebo controlled trial designed to
      determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the
      prevention of male-to-female transmission of HIV among women at high risk.
    
  